ATRA
Bullish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Atara Biotherapeutics, Inc.
- Nom
- Atara Biotherapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $86.2M
- Employés
- 10
- PDG
- Anhco Nguyen
- Site web
- https://www.atarabio.com
- Marché
- CLNNCNTXCOYACSBRIFRXMGNX
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 104 166 titres (~999 993,60 $ US) VENTE TOTALE: 5 062 titres (~40 882,74 $ US)
- Insiders
- Cherry Brian NNguyen AnhCo
- Total bought
-
$999,994
Avg buy (VWAP, 90d window) $9.60 vs last close $9.48 (-1.2%)
- Total sold
-
$40,883
Avg sell (VWAP, 90d window) $8.08 vs last close $9.48 (+17.4%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-04
- Liquidity
- Illiquid $508,893/day · 20d vol
- Last synced
-
2026-10-02 21:10:08
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-04 | Cherry Brian N | Buy · P | 104,166 | $9.60 | $999,994 | Form 4 |
| 2026-08-17 | Nguyen AnhCo | Sell · S | 5,062 | $8.08 | $40,883 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Bullish signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ATRA presents a moderately compelling setup: a meaningful insider cluster buy (~$1M) following Q2 2026 results signals informed confidence in the T-cell immunotherapy pipeline, and the recent shift to profitability…
The first sentence of the analysis written for ATRA on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 0.82 · operating margin 30% — readings disagree
Suggested stop 9.01, nearest stored support minus 0.5 ATR(4.9% under the last close). Reward/risk to the next stored resistance is 0.78. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 82.4% | 83.7% | -3.7% | -324.7% | -1286.4% | |
| Ebit Margin | 30.2% | -62.7% | -3159.1% | -358.5% | -1672.1% | |
| Ebitda Margin | 32.0% | -58.7% | -3102.7% | -349.6% | -1626.1% | |
| Operating Profit Margin | 29.7% | -64.7% | -3219.5% | -441.2% | -1673.9% | |
| Pretax Profit Margin | 27.1% | -66.2% | -3220.7% | -359.1% | -1672.1% | |
| Continuous Operations Profit Margin | 27.1% | -66.2% | -3220.9% | -359.1% | -1672.3% | |
| Net Profit Margin | 27.1% | -66.2% | -3220.9% | -359.1% | -1672.3% | |
| Bottom Line Profit Margin | 27.1% | -66.2% | -3220.9% | -359.1% | -1672.3% | |
| Current Ratio | 0.818 | 0.482 | 0.716 | 3.739 | 3.636 | |
| Quick Ratio | 0.818 | 0.403 | 0.648 | 3.719 | 3.636 | |
| Solvency Ratio | 0.593 | -0.389 | -1.025 | -0.891 | -1.755 | |
| Cash Ratio | 0.568 | 0.186 | 0.182 | 1.178 | 1.003 | |
| Price To Earnings Ratio | 6.931 | -1.167 | -0.197 | -1.465 | -4.340 | |
| Price To Earnings Growth Ratio | -0.056 | 0.014 | -0.012 | 0.038 | 0.350 | |
| Forward Price To Earnings Growth Ratio | -0.056 | 0.014 | -0.012 | 0.038 | 0.350 | |
| Price To Earnings Diluted Ratio | 7.039 | -1.167 | -0.197 | -1.465 | -4.340 | |
| Price To Earnings Diluted Growth Ratio | -0.057 | 0.014 | -0.012 | 0.038 | 0.350 | |
| Price To Book Ratio | -5.894 | -1.024 | -0.547 | 2.642 | 5.280 | |
| Price To Sales Ratio | 1.879 | 0.773 | 6.335 | 5.262 | 72.578 | |
| Price To Free Cash Flow Ratio | -4.455 | -1.445 | -0.280 | -1.218 | -6.388 | |
| Price To Operating Cash Flow Ratio | -4.455 | -1.450 | -0.281 | -1.237 | -6.694 | |
| Debt To Assets Ratio | 2.609 | 0.402 | 0.350 | 0.190 | 0.060 | |
| Debt To Equity Ratio | -1.371 | -0.451 | -0.583 | 0.566 | 0.101 | |
| Debt To Capital Ratio | 3.693 | -0.820 | -1.399 | 0.362 | 0.092 | |
| Long Term Debt To Capital Ratio | -5.605 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | -0.526 | -1.121 | -1.668 | 2.972 | 1.674 | |
| Working Capital Turnover Ratio | -3.337 | -2.344 | 0.098 | 0.257 | 0.057 | |
| Operating Cash Flow Ratio | -3.414 | -0.511 | -1.357 | -3.427 | -2.085 | |
| Operating Cash Flow Sales Ratio | -0.422 | -0.533 | -22.510 | -4.254 | -10.842 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.004 | 1.006 | 1.016 | 1.048 | |
| Debt Service Coverage Ratio | 2.649 | -16.411 | -50.333 | -595.914 | 0.000 | |
| Interest Coverage Ratio | 9.457 | -18.080 | -52.224 | -752.046 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -4.726 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -0.965 | -1.568 | -3.335 | -3.771 | -7.800 | |
| Capital Expenditure Coverage Ratio | 0.000 | -279.337 | -157.790 | -64.496 | -20.843 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | -279.337 | -157.790 | -64.496 | -20.843 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 7.022 | -1.564 | -0.325 | -1.410 | -4.228 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 82.4% | ▼-1.3% | ▲372.2% |
| Ebit Margin | 30.2% | ▲92.9% | ▲1074.6% |
| Ebitda Margin | 32.0% | ▲90.7% | ▲1053.0% |
| Operating Profit Margin | 29.7% | ▲94.4% | ▲1103.6% |
| Pretax Profit Margin | 27.1% | ▲93.3% | ▲1085.3% |
| Continuous Operations Profit Margin | 27.1% | ▲93.3% | ▲1085.4% |
| Net Profit Margin | 27.1% | ▲93.3% | ▲1085.4% |
| Bottom Line Profit Margin | 27.1% | ▲93.3% | ▲1085.4% |
| Current Ratio | 0.818 | ▲0.336 | ▼-1.060 |
| Quick Ratio | 0.818 | ▲0.415 | ▼-1.026 |
| Solvency Ratio | 0.593 | ▲0.982 | ▲1.286 |
| Cash Ratio | 0.568 | ▲0.382 | ▼-0.055 |
| Price To Earnings Ratio | 6.931 | ▲8.098 | ▲6.979 |
| Price To Earnings Growth Ratio | -0.056 | ▼-0.070 | ▼-0.123 |
| Forward Price To Earnings Growth Ratio | -0.056 | ▼-0.070 | ▼-0.123 |
| Price To Earnings Diluted Ratio | 7.039 | ▲8.205 | ▲7.065 |
| Price To Earnings Diluted Growth Ratio | -0.057 | ▼-0.072 | ▼-0.124 |
| Price To Book Ratio | -5.894 | ▼-4.869 | ▼-5.985 |
| Price To Sales Ratio | 1.879 | ▲1.106 | ▼-15.486 |
| Price To Free Cash Flow Ratio | -4.455 | ▼-3.010 | ▼-1.698 |
| Price To Operating Cash Flow Ratio | -4.455 | ▼-3.004 | ▼-1.631 |
| Debt To Assets Ratio | 2.609 | ▲2.208 | ▲1.887 |
| Debt To Equity Ratio | -1.371 | ▼-0.921 | ▼-1.024 |
| Debt To Capital Ratio | 3.693 | ▲4.513 | ▲3.308 |
| Long Term Debt To Capital Ratio | -5.605 | ▼-5.605 | ▼-4.484 |
| Financial Leverage Ratio | -0.526 | ▲0.596 | ▼-0.792 |
| Working Capital Turnover Ratio | -3.337 | ▼-0.993 | ▼-2.283 |
| Operating Cash Flow Ratio | -3.414 | ▼-2.903 | ▼-1.255 |
| Operating Cash Flow Sales Ratio | -0.422 | ▲0.111 | ▲7.290 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | ▼-0.004 | ▼-0.015 |
| Debt Service Coverage Ratio | 2.649 | ▲19.060 | ▲134.651 |
| Interest Coverage Ratio | 9.457 | ▲27.537 | ▲172.036 |
| Short Term Operating Cash Flow Coverage Ratio | -4.726 | ▼-4.726 | ▼-3.781 |
| Operating Cash Flow Coverage Ratio | -0.965 | ▲0.603 | ▲2.523 |
| Capital Expenditure Coverage Ratio | 0.000 | ▲279.337 | ▲104.493 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | ▲279.337 | ▲104.493 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 7.022 | ▲8.586 | ▲7.123 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $226.9M | $99.7M | $54.3M | $334.5M | $1.48B | |
| Enterprise value | $271.2M | $118.5M | $86.3M | $313.3M | $1.40B | |
| EV / Sales | 2.25x | 0.92x | 10.07x | 4.93x | 68.75x | |
| EV / Op. cash flow | -5.33x | -1.72x | -0.45x | -1.16x | -6.34x | |
| EV / Free cash flow | -5.33x | -1.72x | -0.45x | -1.14x | -6.05x | |
| EV / EBITDA | 7.02x | -1.56x | -0.33x | -1.41x | -4.23x | |
| Net debt / EBITDA | 1.15x | -0.25x | -0.12x | 0.10x | 0.23x | |
| Current ratio | 0.82x | 0.48x | 0.72x | 3.74x | 3.64x | |
| Income quality | -1.56x | 0.81x | 0.70x | 1.19x | 0.65x | |
| Graham net-net | -$4 | -$21 | -$43 | $6 | $49 | |
| Tax burden | 99.9% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 89.6% | 105.7% | 102.0% | 100.2% | 100.0% | |
| Working capital | -$2.7M | -$69.7M | -$40.4M | $216.2M | $278.8M | |
| Invested capital | $4.4M | -$28.6M | $18.4M | $290.5M | $358.8M | |
| Return on assets | 161.5% | -78.3% | -166.8% | -60.7% | -72.7% | |
| Operating ROA | 55.5% | -60.8% | -101.9% | -66.4% | -64.5% | |
| Return on tangible assets | 161.5% | -78.3% | -166.8% | -60.7% | -72.7% | |
| Return on equity | -84.9% | 87.8% | 278.3% | -180.3% | -121.6% | |
| Return on invested capital | 222.7% | 721.7% | -778.4% | -90.2% | -93.3% | |
| Return on capital employed | 675.0% | 327.5% | -1185.7% | -94.3% | -94.0% | |
| Earnings yield | 14.4% | -85.7% | -508.4% | -68.2% | -23.0% | |
| Free cash flow yield | -22.4% | -69.2% | -357.6% | -82.1% | -15.7% | |
| Capex / Op. cash flow | 0.0% | -0.4% | -0.6% | -1.6% | -4.8% | |
| Capex / Depreciation | 0.0% | 4.9% | 25.3% | 74.2% | 113.2% | |
| Capex / Sales | 0.0% | 0.2% | 14.3% | 6.6% | 52.0% | |
| SG&A / Sales | 21.7% | 30.9% | 593.8% | 107.2% | 387.4% | |
| R&D / Sales | 31.0% | 117.5% | 2622.0% | 428.7% | 1386.4% | |
| Stock comp / Sales | 8.1% | 20.9% | 529.4% | 84.7% | 264.8% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 4d | 4d | 1452d | 231d | 18d | |
| Days payables outstanding | 2d | 76d | 151d | 9d | 22d | |
| Operating cycle | 4d | 189d | 1851d | 233d | 18d | |
| Cash conversion cycle | 2d | 113d | 1700d | 224d | -5d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-08-12 Atara Biotherapeutics Announces Second Quarter 2026 Financial Results and Operational Progress THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the second quarter 2026 and business updates. “This was an important quarter for Atara. We and our partners, Pierre Fabre Pharmaceuticals (PFP), had a productive Type A meeting with the.
- 2026-06-12 Atara Biotherapeutics Announces Changes to Its Board of Directors THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors. “On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its share.
- 2026-06-11 Quetzal Therapeutics Announces First Patient Dosed in Phase 3 QUATRO-APL Trial of QTX-2101 for Frontline Acute Promyelocytic Leukemia CHICAGO, June 11, 2026 (GLOBE NEWSWIRE) -- Quetzal Therapeutics, a biopharmaceutical company focused on developing therapies for rare hematologic malignancies, today announced that the first patient has been dosed in QUATRO-APL, the company''s global Phase 3 clinical trial evaluating QTX-2101, an investigational oral capsule formulation of arsenic trioxide, in combination with all-trans retinoic acid (ATRA), for the treatment of patients with newly diagnosed, low-risk Acute Promyelocytic Leukemia, or APL.